Cancer NetworkOriginal article
<![CDATA[Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer]]>
Phase 1positiveTG4050Positive
AI Analysis
Summary
MVA-vectored neoantigen vaccine TG4050 demonstrated encouraging safety profile in a Phase 1 trial for resected HPV-negative head and neck cancer, with no dose-limiting toxicities or relapses observed.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
No dose-limiting toxicities or relapses observed in resected HPV-negative HNSCC patients
Importance:5/10
Sentiment:
0.75
neoantigen vaccinehead and neck cancerHNSCCHPV-negativeMVA-vectoredsafetyPhase 1
Read the original article
Published by Cancer Network on September 21, 2026 4:00 PM